Justin Stebbing
Overview
Explore the profile of Justin Stebbing including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
489
Citations
9394
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stebbing J, Bullock A
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 40010768
In this week's Journal for ImmunoTherapy for Cancer, Arai and colleagues analyzed next-generation sequencing data for DNA and RNA from 14,287 patients with colorectal cancer (CRC) categorized by median CD47...
2.
Jain A, Stebbing J
Cancers (Basel)
. 2025 Feb;
17(3).
PMID: 39941863
Understanding the relationship between the Objective Response Rate (ORR) and survival outcomes, notably Progression-Free Survival (PFS) and Overall Survival (OS), is relevant for assessing the efficacy of regimens in oncology....
3.
Wilky B, Schwartz G, Gordon M, El-Khoueiry A, Bullock A, Henick B, et al.
J Clin Oncol
. 2025 Jan;
JCO2402524.
PMID: 39869830
Purpose: Outcomes for patients with advanced sarcomas are poor and there is a high unmet need to develop novel therapies. The purpose of this phase I study was to define...
4.
Adams J, Stebbing J
Int J Cancer
. 2024 Dec;
156(8):1499-1500.
PMID: 39740067
No abstract available.
5.
Bertoldo A, Pizzol D, Yon D, Callegari M, Gobbo V, Cuccurese P, et al.
Int J Mol Sci
. 2024 Dec;
25(23).
PMID: 39684501
Resveratrol is a natural polyphenolic compound that may have multiple influences on human health, including antiaging, anti-inflammatory, anti-neoplastic, antioxidant, insulin-sensitizing, cardioprotective and vasodilating activities. Growing evidence also suggests a potential...
6.
Chand D, Savitsky D, Krishnan S, Mednick G, Delepine C, Garcia-Broncano P, et al.
Cancer Discov
. 2024 Jul;
14(12):2407-2429.
PMID: 39083809
This study reveals that Fc-enhanced anti-CTLA-4 harnesses novel mechanisms to overcome the limitations of conventional anti-CTLA-4, effectively treating poorly immunogenic and treatment-refractory cancers. Our findings support the development of a...
7.
Stiff T, Bayraktar S, Dama P, Stebbing J, Castellano L
Commun Biol
. 2024 Jul;
7(1):859.
PMID: 39003349
Our study employs pooled CRISPR screens, integrating 2D and 3D culture models, to identify miRNAs critical in Breast Cancer (BC) tumoursphere formation. These screens combine with RNA-seq experiments allowing identification...
8.
Glaviano A, Wander S, Baird R, Yap K, Lam H, Toi M, et al.
Drug Resist Updat
. 2024 Jun;
76:101103.
PMID: 38943828
Cell cycle dysregulation is a hallmark of cancer that promotes eccessive cell division. Cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6) are key molecules in the G1-to-S phase cell...
9.
10.
Bullock A, Schlechter B, Fakih M, Tsimberidou A, Grossman J, Gordon M, et al.
Nat Med
. 2024 Jun;
30(9):2558-2567.
PMID: 38871975
Microsatellite stable metastatic colorectal cancer (MSS mCRC; mismatch repair proficient) has previously responded poorly to immune checkpoint blockade. Botensilimab (BOT) is an Fc-enhanced multifunctional anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody...